Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sosei Group Corp.

http://sosei.com

Latest From Sosei Group Corp.

Japan's Biopharma Excellence Celebrated At 2nd Awards

Excellence, innovation, deal-making and personal achievement across the Japanese biopharma sector were celebrated at the Citeline Pharma Intelligence Awards Japan 2023, held in Tokyo on 17 October.

Japan Commercial

Japan's Biopharma Excellence Celebrated At 2nd Awards

Excellence, innovation, deal-making and personal achievement across the Japanese biopharma sector were celebrated at the Citeline Pharma Intelligence Awards Japan 2023, held in Tokyo on 17 October.

Japan Commercial

Finance Watch: UroGen Accesses Cash After Phase III Bladder Cancer Success

Public Company Edition: UroGen raised $120m in a private placement of ordinary shares. Also, Verrica entered into a debt financing for up to $125m upon approval of Ycanth for molluscum contagiosum and job cuts were announced by Homology, Mersana, Infinity and others.

Financing Restructuring

Sosei Builds APAC Independence Through Idorsia Deal

Sosei Heptares' acquisition of Idorsia's ex-China APAC operations will give the Japan-UK group ready-made independent development and commercialization capabilities in Japan, accelerating by "five to 10 years" its goals in its home market, its CEO tells Scrip. The deal also brings a marketed drug and options to selected Idorsia pipeline assets. 

Japan Asia Pacific
See All

Company Information

UsernamePublicRestriction

Register